Should I buy or sell Gossamer Bio stock right now?

5 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for Gossamer Bio in the last year. There are currently 1 hold rating and 4 buy ratings for the stock. The consensus among Wall Street research analysts is that investors should "moderate buy" GOSS shares. View GOSS analyst ratings or view top-rated stocks .

What is Gossamer Bio's stock price target for 2024?

5 brokerages have issued twelve-month target prices for Gossamer Bio's shares. Their GOSS share price targets range from $1.25 to $15.00. On average, they expect the company's share price to reach $7.65 in the next year. This suggests a possible upside of 791.5% from the stock's current price. View analysts price targets for GOSS or view top-rated stocks among Wall Street analysts .

How have GOSS shares performed in 2024?

Gossamer Bio's stock was trading at $0.9125 on January 1st, 2024. Since then, GOSS shares have decreased by 6.0% and is now trading at $0.8581. View the best growth stocks for 2024 here .

When is Gossamer Bio's next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Tuesday, May 14th 2024. View our GOSS earnings forecast .

How were Gossamer Bio's earnings last quarter?

Gossamer Bio, Inc. (NASDAQ:GOSS) released its earnings results on Tuesday, March, 5th. The company reported ($0.21) earnings per share (EPS) for the quarter, hitting analysts' consensus estimates of ($0.21).

What other stocks do shareholders of Gossamer Bio own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Gossamer Bio investors own include Editas Medicine (EDIT) , Alector (ALEC) , Sorrento Therapeutics (SRNE) , Kaleido Biosciences (KLDO) , Homology Medicines (FIXX) , LogicBio Therapeutics (LOGC) , NVIDIA (NVDA) , Stoke Therapeutics (STOK) , Precision BioSciences (DTIL) and Invitae (NVTA) .

When did Gossamer Bio IPO?

Gossamer Bio (GOSS) raised $230 million in an IPO on Friday, February 8th 2019. The company issued 14,400,000 shares at $16.00 per share. BofA Merrill Lynch, Leerink Partners, Barclays and Evercore ISI served as the underwriters for the IPO.

How do I buy shares of Gossamer Bio?

Shares of GOSS stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Compare Top Brokerages Here .

NASDAQ:GOSS

Gossamer Bio (GOSS) Stock Price, News & Analysis

→ A.I. “Perfect Storm” Could Send THESE Stocks Sky High (From InvestorPlace) (Ad)

Free GOSS Stock Alerts

$0.86

-0.04 (-4.45%)

(As of 04/15/2024 ET)

Compare

Today's Range: $0.83
▼
$0.90
50-Day Range: $0.86
▼
$1.51
52-Week Range: $0.45
▼
$1.88

Volume: 915,637 shs
Average Volume: 1.21 million shs
Market Capitalization: $193.57 million

P/E Ratio: N/A
Dividend Yield: N/A
Price Target: $7.65

Get Gossamer Bio alerts:

Gossamer Bio MarketRank™ Stock Analysis

Analyst Rating: Moderate Buy
2.80 Rating Score
Upside/Downside: 791.5% Upside
$7.65 Price Target
Short Interest: Healthy
4.77% of Shares Sold Short
Dividend Strength: N/A
Sustainability: -0.67
Upright™ Environmental Score
News Sentiment: N/A
Insider Trading: Selling Shares
$39,682 Sold Last Quarter
Proj. Earnings Growth: Decreasing
From ($0.75) to ($0.81) Per Share

Overall MarketRank^™

New Rank-Based ScoringMarketRank^™ is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.

4.06 out of 5 stars

Medical Sector

172nd out of 929 stocks

Pharmaceutical Preparations Industry

66th out of 422 stocks

3.4

Analyst's Opinion

Consensus Rating
Gossamer Bio has received a consensus rating of Moderate Buy. The company's average rating score is 2.80, and is based on 4 buy ratings, 1 hold rating, and no sell ratings.
Amount of Analyst Coverage
Gossamer Bio has only been the subject of 4 research reports in the past 90 days.

3.0

Short Interest

Percentage of Shares Shorted
4.77% of the outstanding shares of Gossamer Bio have been sold short.
Short Interest Ratio / Days to Cover
Gossamer Bio has a short interest ratio ("days to cover") of 8.7.
Change versus previous month
Short interest in Gossamer Bio has recently decreased by 2.98%, indicating that investor sentiment is improving.

0.0

Dividend Strength

Dividend Yield
Gossamer Bio does not currently pay a dividend.
Dividend Growth
Gossamer Bio does not have a long track record of dividend growth.

4.7

Sustainability and ESG

Overall ESG (Environmental, Social, and Governance) Score
Gossamer Bio has received a 76.36% net impact score from Upright. The largest positive contribution comes from its "Creating knowledge" impact, which is false driven by its "Preclinical research services for physical health" and "Clinical research services for physical health" products. See details.
Environmental Sustainability
The Environmental Impact score for Gossamer Bio is -0.67.

2.7

News and Social Media Coverage

News Sentiment
Gossamer Bio has a news sentiment score of 0.93. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.66 average news sentiment score of Medical companies.
News Coverage This Week
MarketBeat has tracked 1 news article for Gossamer Bio this week, compared to 2 articles on an average week.
Search Interest
Only 7 people have searched for GOSS on MarketBeat in the last 30 days. This is a decrease of -50% compared to the previous 30 days.
MarketBeat Follows
6 people have added Gossamer Bio to their MarketBeat watchlist in the last 30 days. This is an increase of 50% compared to the previous 30 days.

2.5

Company Ownership

Insider Buying vs. Insider Selling
In the past three months, Gossamer Bio insiders have sold more of their company's stock than they have bought. Specifically, they have bought $0.00 in company stock and sold $39,682.00 in company stock.
Percentage Held by Insiders
Only 9.50% of the stock of Gossamer Bio is held by insiders.
Percentage Held by Institutions
81.23% of the stock of Gossamer Bio is held by institutions. High institutional ownership can be a signal of strong market trust in this company.

0.0

Earnings and Valuation

Earnings Growth
Earnings for Gossamer Bio are expected to decrease in the coming year, from ($0.75) to ($0.81) per share.
Price to Earnings Ratio vs. the Market
The P/E ratio of Gossamer Bio is -0.62, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.
Price to Earnings Ratio vs. Sector
The P/E ratio of Gossamer Bio is -0.62, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.
Price to Book Value per Share Ratio
Gossamer Bio has a P/B Ratio of 3.06. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities.

See Top Rated MarketRank™ Stocks Here

Ad InvestorPlace

REVEALED: Elon Musk’s Secret A.I. Facility?

I recently shot this video outside what could be Elon Musk’s biggest secret. What’s happening inside these walls is so important that our government has declared it a matter of national security.

Click here to see the details because there’s a lot of money at stake.

About Gossamer Bio Stock (NASDAQ:GOSS)

Gossamer Bio, Inc., a clinical-stage biopharmaceutical company, focuses on discovering, acquiring, developing, and commercializing therapeutics in the disease areas of immunology, inflammation, and oncology in the United States. The company is developing GB002, an inhaled, small molecule, platelet-derived growth factor receptor, or PDGFR, colonystimulating factor 1 receptor, or CSF1R, and c-KIT inhibitor for the treatment of pulmonary arterial hypertension; GB004, a gut-targeted, oral small molecule for the treatment of inflammatory bowel disease; GB5121, an oral, irreversible, covalent, small molecule inhibitor of Bruton's Tyrosine Kinase for the treatment of primary central nervous system lymphoma; and GB7208, an oral, small molecule, BTK inhibitor for the treatment of multiple sclerosis. It has license agreements with Pulmokine, Inc. to develop and commercialize GB002 and related backup compounds; and Aerpio Pharmaceuticals, Inc. to develop and commercialize GB004 and related compounds. The company was formerly known as FSG, Bio, Inc. and changed its name to Gossamer Bio, Inc. in 2017. Gossamer Bio, Inc. was incorporated in 2015 and is headquartered in San Diego, California.

GOSS Stock Price History

30 days | 90 days | 365 days | Advanced Chart

GOSS Stock News Headlines

March 29, 2024 | insidertrades.com

Gossamer Bio, Inc. (NASDAQ:GOSS) CEO Faheem Hasnain Sells 23,172 Shares

April 6, 2024 | americanbankingnews.com

Gossamer Bio (NASDAQ:GOSS) Receives New Coverage from Analysts at Wedbush

April 16, 2024 | TradeSmith (Ad)

A.I. Pioneer Issues Urgent Warning to Americans

With artificial intelligence creeping into every facet of our lives, what should you be doing to "A.I.-Proof" your future? It's the question on many of our minds.

March 27, 2024 | markets.businessinsider.com

Buy Rating Affirmed on Gossamer Bio with Promising Seralutinib Prospects in PAH Treatment Landscape

March 21, 2024 | investing.com

Gossamer Bio EVP sells over $5,000 in company stock

March 21, 2024 | investing.com

Gossamer Bio executive sells over $5,000 in company stock

March 21, 2024 | markets.businessinsider.com

Analysts Offer Insights on Healthcare Companies: Diamedica Therapeutics (DMAC), Gossamer Bio (GOSS) and Vor Biopharma (VOR)

March 16, 2024 | ca.finance.yahoo.com

GOSS Apr 2024 1.500 put

April 16, 2024 | TradeSmith (Ad)

A.I. Pioneer Issues Urgent Warning to Americans

With artificial intelligence creeping into every facet of our lives, what should you be doing to "A.I.-Proof" your future? It's the question on many of our minds.

March 16, 2024 | finance.yahoo.com

GOSS Apr 2024 1.000 put

March 13, 2024 | theguardian.com

Tara Rae Moss: ‘So many doctors in different continents told me that I would never recover’

March 12, 2024 | finance.yahoo.com

Gossamer Bio Announces Appointment of Steven D. Nathan, M.D., and Skye Drynan to its Board of Directors

March 12, 2024 | businesswire.com

Gossamer Bio Announces Appointment of Steven D. Nathan, M.D.

March 11, 2024 | markets.businessinsider.com

Barclays Keeps Their Hold Rating on Gossamer Bio (GOSS)

March 7, 2024 | markets.businessinsider.com

Optimistic Buy Rating for Gossamer Bio Amidst Progress in PAH Treatment Market

March 6, 2024 | markets.businessinsider.com

Gossamer Bio Earns ‘Buy’ Rating from Analyst Citing Progress in Seralutinib Trials and Strategic Market Expansion

March 5, 2024 | investorplace.com

GOSS Stock Earnings: Gossamer Bio Meets EPS for Q4 2023

March 5, 2024 | markets.businessinsider.com

Gossamer Bio Posts Narrower Loss In Q4 - Quick Facts

March 5, 2024 | businesswire.com

Gossamer Bio Announces Fourth Quarter and Full-Year 2023 Financial Results and Provides Business Update

February 22, 2024 | benzinga.com

Gossamer Bio Stock (NASDAQ:GOSS) Dividends: History, Yield and Dates

February 16, 2024 | investing.com

Gossamer Bio Inc (GOSS)

February 8, 2024 | finance.yahoo.com

7 Micro-Cap Stocks That Could Majorly Surprise Investors

February 3, 2024 | thestreet.com

Gossamer Bio Inc.

January 22, 2024 | insidermonkey.com

5 Small-Cap Stocks with High Potential

January 8, 2024 | markets.businessinsider.com

Analysts Offer Insights on Healthcare Companies: Ligand Pharma (LGND), Neurogene (NGNE) and Gossamer Bio (GOSS)

January 8, 2024 | markets.businessinsider.com

HC Wainwright & Co. Maintains Buy Rating for Gossamer Bio: Here's What You Need To Know

December 21, 2023 | markets.businessinsider.com

Seralutinib’s Promising Efficacy and Market Potential Reinforce Buy Rating

See More Headlines

Receive GOSS Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Gossamer Bio and its competitors with MarketBeat's FREE daily newsletter.

Company Calendar

Last Earnings: 3/05/2024
Today: 4/15/2024
Next Earnings (Estimated): 5/14/2024
Fiscal Year End: 12/31/2024

Get Stock Alerts

Industry, Sector and Symbol

Stock Exchange: NASDAQ
Sector: Medical
Industry: Pharmaceutical preparations
Sub-Industry: N/A
Current Symbol: NASDAQ:GOSS
CUSIP: N/A
CIK: 1728117
Web: www.gossamerbio.com
Phone: (858) 684-1300
Fax: N/A
Employees: 135
Year Founded: N/A

Price Target and Rating

Average Stock Price Target: $7.65
High Stock Price Target: $15.00
Low Stock Price Target: $1.25
Potential Upside/Downside: +791.5%
Consensus Rating: Moderate Buy
Rating Score (0-4): 2.80
Research Coverage: 5 Analysts

Profitability

EPS (Most Recent Fiscal Year): ($1.39)
Trailing P/E Ratio: N/A
Forward P/E Ratio: N/A
P/E Growth: N/A
Net Income: $-179,820,000.00
Net Margins: N/A
Pretax Margin: N/A
Return on Equity: -944.79%
Return on Assets: -67.76%

Debt

Debt-to-Equity Ratio: 3.14
Current Ratio: 5.94
Quick Ratio: 5.94

Sales & Book Value

Annual Sales: N/A
Price / Sales: N/A
Cash Flow: N/A
Price / Cash Flow: N/A
Book Value: $0.28 per share
Price / Book: 3.06

Miscellaneous

Outstanding Shares: 225,580,000
Free Float: 204,152,000
Market Cap: $193.57 million
Optionable: Optionable
Beta: 1.71

5G Stocks: The Path Forward is Profitable

Click the link below and we'll send you MarketBeat's guide to investing in 5G and which 5G stocks show the most promise.

Get This Free Report

Key Executives

Mr. Faheem Hasnain (Age 66)
Co-Founder, CEO, President & Chairman
Comp: $902.52k
Mr. Bryan Giraudo (Age 49)
COO & CFO
Comp: $690.59k
Dr. Richard Aranda M.D. (Age 63)
Chief Medical Officer
Comp: $625.24k
Mr. Christian Waage (Age 57)
Executive Vice President of Technical Operations & Administration
Comp: $583.16k
Mr. Jeff Boerneke
General Counsel & Secretary
Ms. Deanna Weber
Senior Vice President of Human Resources
Mr. Mario Orlando
Senior Vice President of Commercial New Product Planning
Ms. Caryn L. Peterson (Age 65)
Executive Vice President of Regulatory Affairs
Mr. Matt Cravets
Senior Vice President of Biometrics
Dr. Lisa Elizabeth Nolan Ph.D. (Age 62)
MD & President of Gossamer Bio Ireland

Key Competitors

View All Competitors

Insiders & Institutions

View All Insider Transactions
View All Institutional Transactions

GOSS Stock Analysis - Frequently Asked Questions

Should I buy or sell Gossamer Bio stock right now?: 5 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for Gossamer Bio in the last year. There are currently 1 hold rating and 4 buy ratings for the stock. The consensus among Wall Street research analysts is that investors should "moderate buy" GOSS shares.
View GOSS analyst ratings or view top-rated stocks.
What is Gossamer Bio's stock price target for 2024?: 5 brokerages have issued twelve-month target prices for Gossamer Bio's shares. Their GOSS share price targets range from $1.25 to $15.00. On average, they expect the company's share price to reach $7.65 in the next year. This suggests a possible upside of 791.5% from the stock's current price.
View analysts price targets for GOSS or view top-rated stocks among Wall Street analysts.
How have GOSS shares performed in 2024?: Gossamer Bio's stock was trading at $0.9125 on January 1st, 2024. Since then, GOSS shares have decreased by 6.0% and is now trading at $0.8581.
View the best growth stocks for 2024 here.
When is Gossamer Bio's next earnings date?: The company is scheduled to release its next quarterly earnings announcement on Tuesday, May 14th 2024.
View our GOSS earnings forecast.

How were Gossamer Bio's earnings last quarter?: Gossamer Bio, Inc. (NASDAQ:GOSS) released its earnings results on Tuesday, March, 5th. The company reported ($0.21) earnings per share (EPS) for the quarter, hitting analysts' consensus estimates of ($0.21).
What other stocks do shareholders of Gossamer Bio own?: Based on aggregate information from My MarketBeat watchlists, some companies that other Gossamer Bio investors own include Editas Medicine (EDIT), Alector (ALEC), Sorrento Therapeutics (SRNE), Kaleido Biosciences (KLDO), Homology Medicines (FIXX), LogicBio Therapeutics (LOGC), NVIDIA (NVDA), Stoke Therapeutics (STOK), Precision BioSciences (DTIL) and Invitae (NVTA).
When did Gossamer Bio IPO?: Gossamer Bio (GOSS) raised $230 million in an IPO on Friday, February 8th 2019. The company issued 14,400,000 shares at $16.00 per share. BofA Merrill Lynch, Leerink Partners, Barclays and Evercore ISI served as the underwriters for the IPO.
How do I buy shares of Gossamer Bio?: Shares of GOSS stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.
Compare Top Brokerages Here.

This page (NASDAQ:GOSS) was last updated on 4/16/2024 by MarketBeat.com Staff

From Our Partners

Get 30 Days of MarketBeat All Access Free

Best-in-Class Portfolio Monitoring
View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio.
Stock Ideas and Recommendations
Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report.
Advanced Stock Screeners and Research Tools
Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis.

Start Your 30-Day Free Trial